





RealRate

MEDICINAL PRODUCTS 2022

NUTRA PHARMA CORP Rank 50 of 51



The relative strengths and weaknesses of NUTRA PHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NUTRA PHARMA CORP compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 346% points. The greatest weakness of NUTRA PHARMA CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is -275%, being 261% points below the market average of -14%.

Input Variable	Value in 1000 USD
Assets, Current	534
Assets, Non-Current	94
General and Administrative Expense	1,929
Goodwill	0
Liabilities, Current	21,140
Liabilities, Non-Current	0
Other Assets	108
Other Compr. Net Income	0
Other Expenses	158
Other Liabilities	517
Other Net Income	-11,107
Other Revenues	98
Property, Plant and Equipment, Net	45
Research and Development	0

Output Variable	Value in 1000 USD
Liabilities	21,658
Assets	780
Expenses	2,086
Revenues	98
Stockholders Equity	-20,878
Net Income	-13,096
Comprehensive Net Income	-13,096
Economic Capital Ratio	-275%